Keywords: Grifols, Talecris Biothera, Consent agreement, Antitrust, Blood plasma products, FTC

Grifols closer to Talecris acquisition, but must sell assets

Article | 03 May 2011

Print This

Spanish health care group Grifols (GRLS: MC) and acquisition target Talecris Biotherapeutics (Nasdaq: TLCR) of the USA have signed a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in